Re: FULL Micro Focus Net Express 4.0 University Edition.isol
Mandi Tofolla
Oral administration of sauerkraut juices in Wistar rats led to increased activity of glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1), key liver and kidney detoxifying enzymes [94]. Certain lactic acid bacteria contained in sauerkraut generate conjugated linoleic acid [95], for which there is evidence of anti-carcinogenic and anti-atherosclerotic activity in animals [96,97]. Furthermore, Lactobacillus plantarum P2 isolated from sauerkraut significantly induced TNF-α and IL-12 expression and prevented adhesion and invasion of Caco-2 cells by Salmonella enteritidis [98]. Sauerkraut contains glucosinolate breakdown products including kaempferol, (a flavonoid) isothiocyanates, indole-3-carbinol, goitrin, allyl cyanide and nitriles [99]. The relevance of such phytochemicals to human health is unclear, however kaempferol has been shown to have radical scavenging activity, to protect from oxidative damage and to attenuate cytokine-induced reactive oxygen species in vitro [100]. Isothiocyanates have been shown to have antimicrobial properties, preventing the growth of a range of species, including E. coli, C. difficile, C. jejuni and C. perfringens [101].
Prior to fermentation, the kimchi mix contains a variety of different bacterial species within the Leuconostoc, Lactobacillus, Pseudomonas, Pantoea and Weissella genera [21] (Table 1). However, once fermentation has started, the bacterial diversity decreases and the bacterial community is rapidly dominated by the genus Leuconostoc within only three days of fermentation [21]. Within this genus, Leuconostoc citreum is the most abundant species prior to fermentation, but it is present in only a minor proportion after three days of fermentation, at which time point Leuconostoc gasicomitatum and Leuconostoc gelidum become dominant [21]. As kimchi can comprise a variety of ingredients, the microbial composition varies depending on the type and amount of the foods included. For example, a higher Lactobacillus concertation has been found when kimchi contains a higher garlic quantity [146], while the addition of red pepper powder leads to higher Weissella and lower Leuconostoc and Lactobacillus proportions [147]. Several archaea (e.g., Halococcus, Natronococcus) and yeast (e.g., Saccharomyces, Candida, Trichosporon) genera have also been identified in commercially available kimchi [22] (Table 3). An animal study showed that kimchi consumption, which contained Leuconostoc mesenteroides DRC 0211, may exhibit potential weight control properties in mice via reducing hepatic mRNA expression of adipogenesis-related genes and inflammation-related monocyte chemotactic protein-1 and interleukin-6 in epididymal fat tissue [148]. Reductions in serum total cholesterol, triglycerides, low-density lipoprotein cholesterol levels and atherogenic index have also being demonstrated in rats following consumption of kimchi fermented by Leuconostoc kimchi GJ2 [149]. A human study demonstrated that consumption of kimchi fermented for 8 weeks led to changes in expression of genes related to metabolic pathways and immunity [150]. In a mouse colitis model, Lactobacillus paracasei LS2, a strain isolated from kimchi, decreased cytokine production, myeloperoxidase activity, and the number of macrophages and neutrophils in the lamina propria lymphocytes, suggesting a potential anti-inflammatory effect [151]. Anti-carcinogenic properties have also been attributed to kimchi with an in vitro study demonstrating inhibition of gastric cancer cell growth [152]. Notably, as kimchi comprises a variety of ingredients, its impact on the gut microbiota and health is thought to result from a synergic effect of the microorganisms it contains, as well as the nutrient content (e.g., phytochemicals, fibre, vitamins) of the foods used in the preparation. For example, antimicrobial and antioxidant effects have also been attributed to food constituent of kimchi, such as red pepper seeds and garlic [153,154].
Here is a link into the documentation showing an explanation:
=%2Fcom.microfocus.eclipse.infocenter.visualcobol.vs2012%2FGUID-6081411C-F6E2-42BC-8FD8-3C748C9C05A8.html
It is a permissions problem with the "system directory" of the server/region, caused by trying to start or stop the server/region using a different UNIX user-id than the user-id used on the prior occasion.
The system directory is where files such as the console.log, log-1.html, etc are kept. The directory is created and owned by the user-id that last started the server/region, and if you try to start the server/region with a different user-id, there will be a permissions problem on the system directory.
The quickest way to overcome this problem is to remove or re-name the existing system directory. The system directory is named after the server/ region, and by default it is located in /var/mfcobol/es, though the location can be configured using the "casperm" command or by modifying the file $COBDIR/etc/cas/cas.cfg. To reveal the current location, enter:
grep CASROOT $COBDIR/etc/cas/cas.cfg
After the existing system directory is removed or re-named, then when the server is next started, it will create a new system directory, and will start successfully.
If you start the server/region by clicking the "Start" button on the ES Admin page, then the UNIX-userid will be the "Default startup process user ID" that you see on the Start page. But if you use "casstart" or "casstop" from the command line, you could possibly be logged in as a different user-id. The long-term solution to this problem is to use the same user-id to start the server/region each time. If you want to use "casstart" or "casstop", and sometimes you also want to use the "Start" and "Stop" buttons on the ES Admin page, then when you use "casstart" or "casstop", make sure you are logged in as the "Default startup process user ID" from the Start page.
The majority of clinical isolates of S aureus express a surfacepolysaccharide of either serotype 5 or 8. This has been called a microcapsulebecause it can be visualized only by electron microscopy after antibodylabeling, unlike the copious capsules of other bacteria which are visualized bylight microscopy. S aureus isolated from infections expresseshigh levels of polysaccharide but rapidly loses it upon laboratory subculture.The function of the capsule is not clear. It may impede phagocytosis, but in invitro tests this was only demonstrated in the absence of complement. Conversely,comparing wild-type and a capsule defective mutant strain in an endocarditismodel suggested that polysaccharide expression actually impeded colonization ofdamaged heart valves, perhaps by masking adhesins.
Sorry, I meant that the trial evaluation copy and the Personal Edition have different licenses. The actual installer is the same so you can use the one that you have already. Try Activating the product which should allow you to download the license file. If after installing the license it doesn't show as a PE version then send me an email at chris....@microfocus.com and I will provide you with the correct license. Regardless, if it is a trial license then the product should still work. You might want to do a Repair on VS2022 before you install Visual COBOL.
Our stereo microscope motorized focus drive makes digital documentation with extended focal imaging (EFI) efficient and fully automatic. This even enables the creation of pseudo 3D images. The software offers tools for simple 2D measurements up to complex phase analysis and support many operations including observation, report generation, database creation, and archiving.
aa06259810